ArticleCancer research2019
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Rapid activation of ARF6 after RAF inhibition augments BRAFOncogene · 2026Article
- ARF6 promotes the nuclear translocation of β-catenin to facilitate AFP deficiency-mediated metastasis in CTNNB1Cell biology and toxicology · 2026Article
- Spatial-aware detection of copy number alterations from spatial transcriptomics using SpaCNA.Nature communications · 2026Article
- The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.Haematologica · 2026Article
- Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance.Research square · 2025Article
- Cytohesin-4/ARF6 facilitates the progression of acute myeloid leukemia through activating PIK3R5/PI3K/AKT pathway.iScience · 2025Article
- Invadopodia in cancer metastasis: dynamics, regulation, and targeted therapies.Journal of translational medicine · 2025Review
- ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension.American journal of respiratory cell and molecular biology · 2025Article
- PDGFRα signaling regulates Srsf3 transcript binding to affect PI3K signaling and endosomal trafficking.eLife · 2024Article
- PDGFRα signaling regulates Srsf3 transcript binding to affect PI3K signaling and endosomal trafficking.bioRxiv : the preprint server for biology · 2024Article
- Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy.Nature communications · 2024Article
- Extracellular Vesicles in Malaria: Shedding Light on Pathogenic Depths.ACS infectious diseases · 2024Review
- ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.bioRxiv : the preprint server for biology · 2023Article
- Pals1 functions in redundancy with SMAP1 to inhibit Arf6 in order to prevent Rac1-dependent colorectal cancer cell migration and invasion.Cancer gene therapy · 2023Article
- VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis.Cell reports · 2023Article
- Signal pathways of melanoma and targeted therapy.Signal transduction and targeted therapy · 2021Review
- Unraveling the Relevance of ARL GTPases in Cutaneous Melanoma Prognosis through Integrated Bioinformatics Analysis.International journal of molecular sciences · 2021Article
- An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism.Nature communications · 2021Article
- Review
- Long Non-Coding RNA MDFIC-7 Promotes Chordoma Progression Through Modulating the miR-525-5p/ARF6 Axis.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Jae Hyuk Yoo *Department of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.
Samuel W Brady *Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah.
Lehi Acosta-AlvarezDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Aaron RogersDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Jingfu PengDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Lise K SorensenDepartment of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-3250-4564
Roger K WolffDepartment of Pathology, University of Utah, Salt Lake City, Utah.
Tara MleynekDepartment of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.
Donghan ShinDepartment of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.
Coulson P RichDepartment of Pathology, University of Utah, Salt Lake City, Utah.
David A KircherDepartment of Oncological Sciences, School of Medicine, University of Utah, Salt Lake City, Utah.
Andrea BildDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah.
Shannon J OdelbergDepartment of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.
Dean Y LiDepartment of Medicine, Program in Molecular Medicine, University of Utah, Salt Lake City, Utah.
Sheri L HolmenHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.ORCID 0000-0002-6411-6032
Allie H GrossmannDepartment of Pathology, University of Utah, Salt Lake City, Utah. allie.grossmann@path.utah.edu.ORCID 0000-0002-7665-1403
University of Utah · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MTRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6MProject 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5MEfficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7MNew Therapies to Restore Vascular Integrity During SepsisR01HL130541 · NHLBI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J, WEYRICH, ANDREW S · 2016 to 2020
$3.7MIdentifying a nodal point for G alpha q signaling in eye diseaseR01CA202778 · NCI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J · 2016 to 2020
$1.7MThe Role of the Vasculature in the Pathogenesis of ArthritisR01AR064788 · NIAMS · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J · 2013 to 2017
$1.6MThe Role of the Small GTPase ARF6 in Oncogenic Signaling and TumorigenesisK08CA188563 · NCI · UNIVERSITY OF UTAH · PI GROSSMANN, ALLIE H. · 2015 to 2019
$902kNCRR Confocal ProposalS10RR024761 · NCRR · UNIVERSITY OF UTAH · PI RODESCH, CHRISTOPHER K · 2008 to 2008
$475kARF6 function in cancers driven by RAS hyperactivationK99CA230312 · NCI · UNIVERSITY OF UTAH · PI YOO, JAE HYUK · 2018 to 2019
$260kNCI NIH HHS K08 CA188563NCI NIH HHS K99 CA230312NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA121118NCI NIH HHS R01 CA202778NCI NIH HHS U54 CA209978NCRR NIH HHS S10 RR024761NHLBI NIH HHS R01 HL130541NHLBI NIH HHS T32 HL007576NIAMS NIH HHS R01 AR064788
Abstract
Melanoma has an unusual capacity to spread in early-stage disease, prompting aggressive clinical intervention in very thin primary tumors. Despite these proactive efforts, patients with low-risk, low-stage disease can still develop metastasis, indicating the presence of permissive cues for distant spread. Here, we show that constitutive activation of the small GTPase ARF6 (ARF6
Indexed as
ADP-Ribosylation Factor 6ADP-Ribosylation FactorsAnimalsCyclin-Dependent Kinase Inhibitor p16Guanosine TriphosphateHumansLung NeoplasmsMelanomaMelanoma, ExperimentalMice, Mutant StrainsMice, SCIDNeoplasm MetastasisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseADP-Ribosylation Factor 6ADP-Ribosylation FactorsARF6 protein, humanArf6 protein, mouseBraf protein, mouseCdkn2a protein, mouseCyclin-Dependent Kinase Inhibitor p16Guanosine TriphosphatePhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePten protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.